2012
DOI: 10.1371/journal.pntd.0001390
|View full text |Cite
|
Sign up to set email alerts
|

Improving Access to Medicines for Neglected Tropical Diseases in Developing Countries: Lessons from Three Emerging Economies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0
2

Year Published

2013
2013
2022
2022

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 9 publications
0
6
0
2
Order By: Relevance
“…Social inequities determine the persistence and the difficulties of controlling NTD, causing higher vulnerability and risk for these diseases 11 . Poverty is one of the determining factors for the occurrence and transmission of leprosy 7 , 13 , 14 .…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Social inequities determine the persistence and the difficulties of controlling NTD, causing higher vulnerability and risk for these diseases 11 . Poverty is one of the determining factors for the occurrence and transmission of leprosy 7 , 13 , 14 .…”
Section: Discussionmentioning
confidence: 99%
“…Leprosy is a Neglected Tropical Disease (NTD) with unequal occurrence, mainly in socioeconomically disadvantaged and marginalized populations in tropical countries 11 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…While several large international foundations (such as the Gates and Clinton Foundations) have successfully negotiated reduced prices for medicines by guaranteeing purchases and continuous demand, such strategies only address a fraction of the access gap. Similarly, donation programs, albeit commendable, fail to address the systemic challenges requiring sustainable commitments and strategies (Holt, Gillam and Ngondi, 2012).…”
Section: Access To Health Goodsmentioning
confidence: 99%
“…Without adequate systems to deliver medicines to people, access gaps in LMICs cannot be ameliorated. For example, India has a thriving generics industry that is capable of ensuring the domestic supply of affordable medicines, yet large sections of Indian society remain without access to these (Holt et al, ). The value and benefit of medical innovation derives from its availability to those who need it.…”
Section: The Twin Challenge Of Innovation and Accessmentioning
confidence: 99%